ABSTRACT
Child maltreatment (CM) is a global public health problem. Evidence-based home visiting programs, such as SafeCare®, reduce CM risk, and enhance parent-child relationships and other protective factors. As the result of the COVID-19 pandemic and resulting restrictions, SafeCare Providers transitioned from home to virtual delivery for the SafeCare curriculum. The purpose of this study is to 1) examine active SafeCare Providers' opinions on the feasibility and effectiveness of SafeCare via remote delivery, and 2) better understand workforce concerns for human service professionals within the context of COVID-19 mitigation efforts. Data are from a cross-sectional survey of SafeCare Providers (N = 303) in the United States, Canada, and Australia. The majority of Providers reported they were actively delivering SafeCare virtually and were comfortable with the delivery format. Providers indicated that the majority of SafeCare families are making progress on target skills, and that engagement is high among many families. Some service delivery challenges were reported, ranging from family data plan limitations to difficulty with delivery of specific components of the SafeCare curriculum related to modeling and assessment. The impact of COVID-19 on Providers' daily routines, stress level, and work-life balance has been significant. Remote, virtual delivery of CM prevention programming offers the opportunity to continue serving vulnerable families in the midst of a pandemic. Barriers related to family technology and data access must be addressed to ensure reach and the effective delivery of prevention programming during the pandemic and beyond.
ABSTRACT
Social skills deficits and excesses are a defining aspect of mental retardation (MR). Research indicates that there is an established relationship between social skills and maladaptive behaviors. A number of studies demonstrate that the social competence of individuals with MR and comorbid psychopathology can be enhanced with social skills training. However, to design an effective training package, an accurate assessment of adaptive and social functioning must first be conducted. Unique problems arise when assessing social skills in individuals with severe and profound MR (i.e., individuals often have limited verbal repertoires). Thus, a clinician must often rely on observable behavior and caregiver report rather than self-report. The three most common methods for assessing social skills are behavioral observations, role-playing, and checklists. These assessment strategies will be discussed, as well as suggestions for future research.
Subject(s)
Behavior Therapy , Intellectual Disability/psychology , Personality Assessment , Social Adjustment , Social Behavior Disorders/diagnosis , Activities of Daily Living/psychology , Adolescent , Adult , Child , Education of Intellectually Disabled , Female , Humans , Intellectual Disability/diagnosis , Intellectual Disability/therapy , Male , Social Behavior Disorders/psychology , Social Behavior Disorders/therapyABSTRACT
Psychotropic medications are frequently prescribed for behavior problems and/or psychopathology among individuals with mental retardation (MR). Unfortunately, the methodological integrity of scientific studies that support the use of medications among this population is often lacking. A recent review of the literature revealed that many of the studies that have assessed the efficacy of psychotropic medications for individuals with MR are methodologically flawed. Thus, we have detailed suggestions to improve the quality of future medication studies and avoid the methodological problems that prevent the scientific advancement of psychopharmacological research among individuals with MR.
Subject(s)
Intellectual Disability/drug therapy , Psychotropic Drugs/therapeutic use , Clinical Trials as Topic , Humans , Intellectual Disability/complications , Intellectual Disability/psychology , Mental Disorders/drug therapy , Mental Disorders/etiology , Psychopharmacology/standards , Psychopharmacology/trends , Psychotropic Drugs/pharmacology , Quality Control , Research DesignABSTRACT
Metoclopramide is an anti-emetic medication that has been associated with movement disorders such as extra-pyramidal reactions and tardive dyskinesia (TD). Reports of these reactions have been documented in the general population, but investigations of side effects in persons with mental retardation are scant. Given the high incidence of gastrointestinal disturbance in persons with mental retardation, and the popularity of this medication to treat such problems, these individuals could be at risk for developing movement disorders resulting from metoclopramide use. We compared incidence rates of TD over a 1-year period in developmentally disabled individuals taking either metoclopramide, typical antipsychotics, or no psychotropic medications (Table 1). Assessment was completed using the Dyskinesia Identification System--Condensed User Scale (DISCUS), a standardized measure of TD found to be reliable and valid for persons with mental retardation. No significant differences in DISCUS scores between the metoclopramide and antipsychotic treated groups were noted across four measurements taken during the course of 1 year. Additionally, no difference was found between these two groups for a number of participants who met criteria for probable TD on at least one of the DISCUS administrations. Comparisons between all three groups on one testing occasion revealed a significant difference between groups. The no psychotropic control group showed significantly less TD symptomology than the antipsychotic or metoclopramide groups.
